Last reviewed · How we verify
NCT02505295
Evaluation of Selenium Supplementation in Ischemic Stroke Outcome
NA trial testing Selenium in Ischemic Stroke in 44 participants. Completed in 1 January 2018.
1 January 2018
Quick facts
| Lead sponsor | Mazandaran University of Medical Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 1 October 2015 |
| Primary completion | 1 January 2018 |
| Estimated completion | 1 January 2018 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Selenium (SELENIUM) — full drug profile →
- normal saline
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
Mazandaran University of Medical Sciences
Who can join
Adults 20 to 85, any sex, with Ischemic Stroke. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
National Institutes of Health Stroke Scale(NIHSS)
Time frame: up to 3 days
The primary outcome of interest in this study was defined as at least 25% reduction in NIHSS score in day 7 or at the discharge in selenium group compared with control; as an indicator of short term outcome. -
modified Rankin Scale (MRS)
Time frame: at day 5-8
The primary outcome of interest in this study was defined as at least 1 point reduction in mRS score in day 7 or at the discharge in selenium group compared with control; as an indicator of short term outcome.
Sponsor's own description
Selenium is a trace element essential to human health.Selenium protection against cellular damage by oxygen radicals is accomplished through selenoproteins. Ischemic stroke is associated with the generation of oxygen free radicals resulting in a condition of oxidative stress. Supplementing stroke patients with antioxidant nutrients may improve survival.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions.
Qin C, Yang S, Chu YH, Zhang H, et al · · 2022 · cited 591× · PMID 35794095 · DOI 10.1038/s41392-022-01064-1
Verify or expand the search:
- PubMed search for NCT02505295
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Selenium
Trials testing the same drug.
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT05672095 — Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · Phase 1, PHASE2 · withdrawn
- NCT06413043 — Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy · NA · not yet recruiting
- NCT06951282 — Impact of Selenium on Methotrexate Induced Spermatotoxicity; A Comparative Study · Phase 1, PHASE2 · completed
- NCT06362005 — The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus · Phase 4 · completed
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Mazandaran University of Medical Sciences trials
Trials by the same sponsor.
- NCT06737406 — Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart · NA · recruiting
- NCT06812000 — Post-stroke Seizure and Epilepsy Following Thrombolytic Therapy · completed
- NCT06653348 — Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke · Phase 2, PHASE3 · recruiting
- NCT07120841 — Nurse Telephone Follow-up for Cardiovascular Patients · NA · completed
- NCT07210450 — Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia · Phase 2, PHASE3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02505295 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mazandaran University of Medical Sciences
- Last refreshed: 22 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02505295.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing